The content on this site is intended for healthcare professionals only
Dr Cruz speaks with ecancer at ESMO 2016 about trials for lurbinectedin in patients for whom PARP inhibition is no longer and option.
She describes the mechanisms by which resistance to other medications can be subverted by lurbinectedin, and reports its suitability even for tumours with resistance to standard therapy cisplatin.
Lurbinectedin is discussed further by Dr Judith Balmaña, who spoke with ecancer here.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma in a resource constrained setting
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert round up July 28th to August 3rd, 2023
Choosing Wisely in radiology Tanzania
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
